CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

Right arrow Help viewing high resolution images
Right arrow Return to article
Click on image to view larger version.



Fig. 1. Substitution of the CAAX motif of RhoA(63L) with the CVLS motif from farnesylated H-Ras results in a protein that is not altered in subcellular location but is sensitive to FTase, but not GGTaseI, inhibitor treatment. A, lysates from NIH 3T3 cells stably or transiently expressing HA epitope-tagged RhoA(63L) proteins were normalized for total protein. The proteins were resolved by SDS-PAGE, and expression was determined by Western blot analysis using anti-HA epitope antibody. B, NIH 3T3 cells transiently expressing the indicated GFP-tagged RhoA(63L) proteins were cultured in growth medium supplemented with vehicle (DMSO), FTI-2153, or GGTI-2166 were analyzed as live cells. Cells were then visualized using a Axioskop 2 microscope and Openlab digital imaging software. C, alternatively prenylated, but not unprenylated, shows a similar subcellular location as geranylgeranylated RhoA(63L). NIH 3T3 cells stably expressing HA epitope-tagged RhoA(63L)-WT, RhoA(63L)-CVLS, and RhoA(63L)-SLVL were fixed, and the proteins were visualized by indirect immunofluorescence analyses using anti-HA epitope antibody and a FITC-conjugated antimouse secondary antibody. Data shown are representative of three independent experiments.





Right arrow Return to article


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation